OncoIndx Assay allows faster, affordable, and deeper coverage of specific biomarkers that can guide precision treatment decisions including Chemotherapy, Targeted Therapy, and Immunotherapy with high precision and reliability. 

Our targeted gene panel is well suited to detect ctDNA in liquid biopsies as well undergo tissue biopsy with high sensitivity and specificity. It can screen both exonic and selected intronic regions of more than 600 genes with known genomic alterations that impact on initiation, development, progression and therapeutic evasion of the disease. The assay detects all classes of genomic alterations, including Single Nucleotide Variants (SNVs), Small Insertions and Deletions (Indels), Copy Number Alterations (Amplifications) and selected Translocations with minimal amounts of routine clinical samples. 

All OncoIndx samples are  also simultaneously profiled for Tumor Mutation Burden (TMB), Microsatellite Instability (MSI) status and Homologous Recombination Deficiency (HRD) to help guide immunotherapy decisions. Additionally, the assay can also be used as a tool to identify pharmacogenomic determinants of toxicity and adverse events in cancer patients.